MoneyWorks4Me

Wanbury - Quaterly Results

16 May 2024 Evaluate
The Total revenue for the quarter ended March 2024 of  Rs. 1394.06 millions remain, more or less, the same.The company almost doubled its revenue to Rs. 80.76 millions  from Rs. 10.15 millions in the quarter ended March 2024.Operating Profit saw a handsome growth to 190.88 millions from 121.02 millions in the quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1394.06 1329.75 4.84 5756.50 4996.47 15.21 5756.50 4996.47 15.21
Other Income 9.25 -20.62 -144.86 29.90 9.13 227.49 29.90 9.13 227.49
PBIDT 190.88 121.02 57.73 729.93 240.85 203.06 729.93 240.85 203.06
Interest 74.60 75.15 -0.73 291.81 213.94 36.40 291.81 213.94 36.40
PBDT 116.28 39.93 191.21 438.12 20.97 1989.27 438.12 20.97 1989.27
Depreciation 32.80 30.73 6.74 130.31 123.85 5.22 130.31 123.85 5.22
PBT 83.48 9.20 807.39 307.81 -102.88 -399.19 307.81 -102.88 -399.19
TAX 2.72 -0.95 -386.32 3.81 1.09 249.54 3.81 1.09 249.54
Deferred Tax 2.72 -0.95 -386.32 3.81 1.09 249.54 3.81 1.09 249.54
PAT 80.76 10.15 695.67 304.00 -103.97 -392.39 304.00 -103.97 -392.39
Equity 327.46 327.06 0.12 327.46 327.06 0.12 327.46 327.06 0.12
PBIDTM(%) 13.69 9.10 50.45 12.68 4.82 163.05 12.68 4.82 163.05
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..